BACKGROUND: In this study, we investigated the expression of HER-2/neu and AR in clinically organ-confined prostate cancer to determine whether alterations in these signaling pathways contribute to the development of metastatic disease. METHODS: HER-2/neu and AR immunoreactivity were evaluated in archived prostatic tissues obtained from 53 men with clinically organ-confined disease who underwent radical prostatectomy. Associations between AR and HER-2/neu immunostaining and disease outcome were determined. RESULTS: Seventy percent (37/53) of tumors exhibited high levels of HER-2/neu immunostaining and 68% (36/53) of tumors had elevated AR levels. Patients with high levels of both HER-2/neu and AR had the highest rate of PSA failure (56%, 15/27) compared with no PSA failures amongst seven patients with low levels of both HER-2/neu and AR (log rank statistic 7.69, P = 0.021). Concurrent high levels of HER-2/neu and AR expression were significantly associated with high pathological stage (P = 0.027) and development of metastatic disease (P = 0.022). CONCLUSIONS: These findings support the notion that both the HER-2/neu and AR signaling pathways may contribute to development of metastatic disease. The subset of prostate tumors with increased HER-2/neu and AR levels may benefit from treatment strategies that target both signaling pathways. (c) 2008 Wiley-Liss, Inc.
BACKGROUND: In this study, we investigated the expression of HER-2/neu and AR in clinically organ-confined prostate cancer to determine whether alterations in these signaling pathways contribute to the development of metastatic disease. METHODS:HER-2/neu and AR immunoreactivity were evaluated in archived prostatic tissues obtained from 53 men with clinically organ-confined disease who underwent radical prostatectomy. Associations between AR and HER-2/neu immunostaining and disease outcome were determined. RESULTS: Seventy percent (37/53) of tumors exhibited high levels of HER-2/neu immunostaining and 68% (36/53) of tumors had elevated AR levels. Patients with high levels of both HER-2/neu and AR had the highest rate of PSA failure (56%, 15/27) compared with no PSA failures amongst seven patients with low levels of both HER-2/neu and AR (log rank statistic 7.69, P = 0.021). Concurrent high levels of HER-2/neu and AR expression were significantly associated with high pathological stage (P = 0.027) and development of metastatic disease (P = 0.022). CONCLUSIONS: These findings support the notion that both the HER-2/neu and AR signaling pathways may contribute to development of metastatic disease. The subset of prostate tumors with increased HER-2/neu and AR levels may benefit from treatment strategies that target both signaling pathways. (c) 2008 Wiley-Liss, Inc.
Authors: Carmela Ricciardelli; Kate M Frewin; Izza de Arao Tan; Elizabeth D Williams; Kenneth Opeskin; Melanie A Pritchard; Wendy V Ingman; Darryl L Russell Journal: Am J Pathol Date: 2011-10-12 Impact factor: 4.307
Authors: Grace L Lu-Yao; Peter C Albertsen; Hui Li; Dirk F Moore; Weichung Shih; Yong Lin; Robert S DiPaola; Siu-Long Yao Journal: Eur Urol Date: 2012-05-10 Impact factor: 20.096
Authors: Robert L Grubb; Jianghong Deng; Peter A Pinto; James L Mohler; Arul Chinnaiyan; Mark Rubin; W Marston Linehan; Lance A Liotta; Emanuel F Petricoin; Julia D Wulfkuhle Journal: J Proteome Res Date: 2009-06 Impact factor: 4.466
Authors: Elizabeth M Williams; John P Higgins; Ankur R Sangoi; Jesse K McKenney; Megan L Troxell Journal: Int Urol Nephrol Date: 2014-09-14 Impact factor: 2.370